The rise of antibiotic
resistance, coupled with increased expectations
for mobility in later life, is creating a need for biofilm inhibitors
and delivery systems that will reduce surgical implant infection.
A limitation of some of these existing delivery approaches is toxicity
exhibited toward host cells. Here, we report the application of a
novel inhibitor of the enzyme, methylthioadenosine nucleosidase (MTAN),
a key enzyme in bacterial metabolic pathways, which include S-adenosylmethionine catabolism and purine nucleotide recycling,
in combination with a poly(vinyl alcohol)-tyramine-based (PVA-Tyr)
hydrogel delivery system. We demonstrate that a lead MTAN inhibitor,
selected from a screened library of 34 candidates, (2S)-2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-ylmethyl)aminoundecan-1-ol
(31), showed a minimum biofilm inhibitory concentration
of 2.2 ± 0.4 μM against a clinical staphylococcal species
isolated from an infected implant. We observed that extracellular
DNA, a key constituent of biofilms, is significantly reduced when
treated with 10 μM compound 31, along with a decrease
in biofilm thickness. Compound 31 was incorporated into
a hydrolytically degradable photo-cross-linked PVA-Tyr hydrogel and
the release profile was evaluated by HPLC studies. Compound 31 released from the PVA-hydrogel system significantly reduced
biofilm formation (77.2 ± 8.4% biofilm inhibition). Finally,
compound 31 released from PVA-Tyr showed no negative
impact on human bone marrow stromal cell (MSC) viability, proliferation,
or morphology. The results demonstrate the potential utility of MTAN
inhibitors in treating infections caused by Gram-positive bacteria,
and the development of a nontoxic release system that has potential
for tunability for time scale of delivery.